QuantRx Biomedical Corporation

Equities

QTXB

US74765N1090

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 01:37:42 2024-02-26 pm EST			5-day change	1st Jan Change
0.004 ^USD	-.--%		-.--%	-49.37%

2022	QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
2022	Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical Corporation	CI

Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 16, 2021 at 05:15 pm EDT

QuantRx Biomedical Corporation announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 23,231 compared to USD 25,440 a year ago. Net loss was USD 76,990 compared to USD 79,331 a year ago. For the half year, operating loss was USD 28,278 compared to USD 40,840 a year ago. Net loss was USD 135,988 compared to USD 124,003 a year ago.

Latest news about QuantRx Biomedical Corporation

QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical Corporation	22-08-24	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
QuantRx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
QuantRx Biomedical Corporation Auditor Raises 'Going Concern' Doubt	22-04-14	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-16	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-17	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-15	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-17	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-20	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-14	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-19	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-15	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-20	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-16	CI
Preprogen LLC acquired the acquisition of certain assets from QuantRx Biomedical Corporation for $1.4 million.	17-12-20	CI
QuantRx Biomedical Corporation cancelled the acquisition of Global Cancer Diagnostics Inc.	16-08-16	CI
QuantRx Biomedical Corporation signed a letter of intent to acquire Global Cancer Diagnostics Inc.	15-09-28	CI
QuantRx Biomedical Corporation Auditor Raises 'Going Concern' Doubt	15-04-14	CI
QuantRx Biomedical Corporation Announces Demise of William Fleming, President, Chief Scientific Officer and Director	15-03-26	CI
QuantRx Biomedical Mulls Strategic Partners For Point Of Care	15-03-19	CI
QuantRx Biomedical Corporation Provides Update on Technological Progress of its Genomic Diagnostics Platforms	15-03-04	CI

Chart QuantRx Biomedical Corporation

Duration

Period

More charts

Company Profile

QuantRx Biomedical Corporation has developed its patented miniform pads and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs (the OTC Business). The Company is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents (the Diagnostics Business). The Company's platforms include inSync, Unique and original equipment manufacturer (OEM) branded over-the-counter and laboratory testing products based on its core intellectual property related to the Company PAD technology. Its OTC Business includes commercialization of its InSync feminine hygienic interlabial pad, the Unique Miniform for hemorrhoid application, and other treated miniforms, as well as maintaining established and continuing licensing relationships related to the OTC Business. It also owns certain diagnostic testing technology that is based on its lateral flow patents.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
QUANTRX BIOMEDICAL CORPORATION	-49.37%	315K
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+1.86%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology